No authorised EU health claim exists for quercetin. This is not an administrative backlog — EFSA formally assessed and rejected four specific proposals in 2011. The growing body of preclinical research from 2024-2026 (including the Life Extension article from September 2026 on atherosclerosis) does not change that legal status, because it concerns animal models, cell lines, and one small perioperative trial — not the proof the EU claims framework requires. Educational material — not medical or legal advice.

Trigger for this article (not a legal source): Life Extension published "Quercetin Reduces Atherosclerosis and Supports Heart Health" (September 2026) and promoted it on X (status 2100404425395151328), describing preclinical research on quercetin and atherosclerosis. The article itself notes the evidence comes from animal and cell models, and that clinical trials in humans are needed to translate these findings into human atherosclerosis outcomes. That is a good starting point for the difference between "an interesting mechanism" and "a health claim on an EU label".
Two columns: EU Register status for quercetin (0 entries) and the 2024-2026 science layer
Fig. 1. Left column: EU Register status — no authorised claims, negative EFSA opinion from 2011. Right column: current science layer — preclinical mechanisms and one small perioperative RCT.

1. Legal status: zero claims, one clear refusal

Regulation (EC) No 1924/2006 prohibits any health claim on food unless it is authorised by the European Commission and included in the Union list (Article 10(1)). Regulation (EU) No 432/2012 lists the authorised Article 13(1) function claims — quercetin is not on that list.

This is not a procedural backlog case, unlike many botanical "on-hold" claims frozen since 2010 (see our article on bay leaf and the SANCO/11074/2013 system). For quercetin, EFSA issued a substantive, negative opinion — the case was assessed and closed with a refusal, not suspended.

2. The 2011 EFSA opinion: four rejected claims

The NDA Panel assessed an Article 13(1) claim in the opinion titled "Scientific Opinion on the substantiation of health claims related to quercetin and protection of DNA, proteins and lipids from oxidative damage (ID 1647), 'cardiovascular system' (ID 1844), 'mental state and performance' (ID 1845), and 'liver, kidneys' (ID 1846)" — EFSA Journal 2011;9(4):2067, DOI 10.2903/j.efsa.2011.2067, published 8 April 2011 as part of the fourth batch of Article 13(1) opinions.

Claim IDProposed claimEFSA outcome
1647Protection of DNA, proteins and lipids from oxidative damageRejected — no evidence of a beneficial physiological effect in humans
1844"Cardiovascular system"Rejected — effect framed too generally to assess
1845"Mental state and performance"Rejected — effect framed too generally to assess
1846"Liver, kidneys"Rejected — effect framed too generally to assess

This outcome fits a broader 2009-2011 pattern: EFSA mass-rejected "antioxidant" claims for dozens of substances (green tea, resveratrol, lycopene, beta-carotene, part of the olive-extract dossiers, among others) on the same basis — "antioxidant activity" or "antioxidant content" alone is not accepted as an established, beneficial physiological effect unless the applicant demonstrates a specific, measurable effect in humans.

For contrast: cocoa flavanols carry a narrow but authorised claim on maintaining blood-vessel elasticity (Reg. 851/2013 and 2015/539) — see our article on cocoa flavanols. That shows membership in the broader polyphenol/flavonoid family does not decide the outcome — the specific evidence for the specific substance and effect does.

3. What newer preclinical research (2024-2026) actually shows

The September 2026 Life Extension article summarises mechanisms reported in preclinical literature: Nrf2 activation via binding to KEAP1, increased SIRT1 expression, AMPK activation, reduced transformation of macrophages into foam cells, protection of endothelial and vascular smooth-muscle cells, and effects on gut microbiota composition. All of these mechanisms are described in animal models (typically ApoE-deficient mice) or cell lines.

A 2026 systematic meta-analysis (Int J Mol Sci, DOI 10.3390/ijms27010527) pooled preclinical studies on quercetin and atherosclerosis, finding reduced aortic plaque area, lower TC/TG/LDL-C, higher HDL-C, and reduced expression of adhesion factors (e.g., VCAM-1) and pro-inflammatory factors (e.g., IL-6) — consistently in animal models, with dose- and duration-dependent effects.

A separate 2026 systematic review (Front Pharmacol, DOI 10.3389/fphar.2026.1863814) on preclinical myocardial ischemia-reperfusion injury found reduced infarct size in animals (SMD −2.98; 95% CI −4.37 to −1.58) — again preclinical, not clinical, data.

Evidence ladder: cellular mechanism → effect in an animal model → (rarely) effect in a small human trial → (even more rarely) a hard endpoint in a large human RCT. The 2026 preclinical reviews and meta-analyses sit on the first two rungs of that ladder.

4. The one relevant human RCT: Q-CABG (Aging Cell 2025)

Q-CABG (ClinicalTrials.gov NCT04907253) is a randomised, double-blind, placebo-controlled phase II trial in patients undergoing CABG surgery. Results were published in Aging Cell 2025 under the title "Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients" (Aging Cell 2025;24(8):e70108).

  • Participants: 97 patients (78 men) undergoing elective CABG surgery.
  • Intervention: quercetin 500 mg twice daily from 2 days pre-surgery through hospital discharge, versus placebo.
  • Primary outcomes: reduced inflammation and improved endothelial function ex vivo.
  • Key result: endothelial function (acetylcholine-induced relaxation) improved significantly overall (p=0.049), with the effect present in men (p=0.043) and absent in women (p=0.852).
  • Postoperative atrial fibrillation: significantly lower incidence in the quercetin group — 4% versus 18% with placebo (p=0.033).
  • CRP: a trend toward reduction at discharge (p=0.073) — did not reach statistical significance.
  • Sex-dependent mechanism: internal thoracic artery transcriptomics showed quercetin reversed overexpression of cellular senescence pathways in men; in women, endothelial benefit was minimal, and fibroblasts showed increased senescence-associated inflammation.
What this trial does not prove: it is a short-term (days), perioperative study in a small sample, using surrogate endpoints (ex vivo endothelial function, inflammatory markers, atrial fibrillation) — not hard clinical endpoints such as heart attack, stroke, or cardiovascular death in the general population. The effect is clearly sex-dependent. It is a meaningful scientific signal, not a substitute for the evidence required to authorise a health claim under Regulation 1924/2006.

5. Why "promising mechanisms" don't open the door to a label claim

Regulation 1924/2006 requires demonstrating a cause-and-effect relationship between consuming a specific substance at a realistic dose and a specific, measurable, beneficial physiological effect in humans — ideally in randomised intervention trials with relevant endpoints. Animal models and cell lines provide mechanistic hypotheses, not regulatory proof. Even a positive signal from one small human RCT (like Q-CABG) is not sufficient — it would need to be replicated, extended to a broader population, and formally submitted to EFSA as a new Article 13(5) application with full scientific documentation.

Until then, the 2011 EFSA opinion remains current law: quercetin has no authorised claim in any of the assessed categories — antioxidant, cardiovascular, mental, or liver/kidney.

6. Practical line for quercetin supplement manufacturers

ChannelLower riskHigher risk
LabelIngredient name, amount per serving, source description (e.g., "a flavonoid found in onions and apples")"Supports heart health", "protects against atherosclerosis", "antioxidant properties" as a health claim
Web / socialAccurate research summary with a "preclinical / small clinical trial" caveatCiting animal mechanisms as a promise of human effect
Study referencesLink to the publication with a clear description of population and study stagePresenting Q-CABG as proof of a general "heart" benefit without noting the sex-dependent effect
Compliance documentationTracking the EU Register and EFSA opinion 2011;9(4):2067Assuming new scientific publications automatically open a new claim

Conclusion

The split between the two layers is unusually clean here: the science layer is evolving (new preclinical mechanisms, one promising but narrow and sex-dependent perioperative RCT), while the legal layer has stood still since 2011 — zero authorised claims, one clear, substantive refusal covering exactly the categories that show up most often in quercetin supplement marketing: antioxidant, heart, mental, liver and kidney. A manufacturer who communicates the mechanism with the right scientific caveat is in a different legal position than one who turns that mechanism into a health promise on the label.

Educational material, not legal or medical advice. The legal qualification of specific marketing communication depends on exact wording, context and channel; when in doubt, obtain an individual compliance assessment.

Primary sources

  1. Regulation (EC) No 1924/2006 — Article 10(1)
  2. Commission Regulation (EU) No 432/2012 — Article 13(1) claims list
  3. Regulation (EU) No 1169/2011 — Article 7(3)
  4. EFSA NDA Panel. Scientific Opinion — quercetin and protection of DNA, proteins and lipids from oxidative damage (ID 1647), "cardiovascular system" (ID 1844), "mental state and performance" (ID 1845), and "liver, kidneys" (ID 1846). EFSA Journal 2011;9(4):2067. DOI 10.2903/j.efsa.2011.2067
  5. Life Extension Magazine. Quercetin Reduces Atherosclerosis and Supports Heart Health (September 2026)
  6. Life Extension — X status (article trigger; not a legal source)
  7. Q-CABG trial. Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients. Aging Cell 2025;24(8):e70108
  8. ClinicalTrials.gov NCT04907253 — Quercetin in Coronary Artery By-pass Surgery
  9. Evidence Synthesis and Mechanism Analysis of Quercetin Treatment for Atherosclerosis: A Preclinical Systematic Review and Meta-Analysis. Int J Mol Sci 2026;27(1):527
  10. Quercetin-associated cardioprotection in preclinical myocardial ischemia-reperfusion injury: a systematic review and meta-analysis. Front Pharmacol 2026